Back to Search Start Over

Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection.

Authors :
O'Laughlin, Kelli N
Chi, Gerald1
O'Laughlin, Kelli N
Thompson, Matthew
Hota, Bala
Gottlieb, Michael
Plumb, Ian D
Chang, Anna Marie
Wisk, Lauren E
Hall, Aron J
Wang, Ralph C
Spatz, Erica S
Stephens, Kari A
Huebinger, Ryan M
McDonald, Samuel A
Venkatesh, Arjun
Gentile, Nikki
Slovis, Benjamin H
Hill, Mandy
Saydah, Sharon
Idris, Ahamed H
Rodriguez, Robert
Krumholz, Harlan M
Elmore, Joann G
Weinstein, Robert A
Nichol, Graham
INSPIRE Investigators
O'Laughlin, Kelli N
Chi, Gerald1
O'Laughlin, Kelli N
Thompson, Matthew
Hota, Bala
Gottlieb, Michael
Plumb, Ian D
Chang, Anna Marie
Wisk, Lauren E
Hall, Aron J
Wang, Ralph C
Spatz, Erica S
Stephens, Kari A
Huebinger, Ryan M
McDonald, Samuel A
Venkatesh, Arjun
Gentile, Nikki
Slovis, Benjamin H
Hill, Mandy
Saydah, Sharon
Idris, Ahamed H
Rodriguez, Robert
Krumholz, Harlan M
Elmore, Joann G
Weinstein, Robert A
Nichol, Graham
INSPIRE Investigators
Source :
PloS one; vol 17, iss 3, e0264260; 1932-6203
Publication Year :
2022

Abstract

BackgroundReports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported outcomes with data from digital health records to understand predictors and impacts of SARS-CoV-2 infection.MethodsINSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of SARS-CoV-2 infection in eight regions across the US. Adults are eligible for enrollment if they are fluent in English or Spanish, reported symptoms suggestive of acute SARS-CoV-2 infection, and if they are within 42 days of having a SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test), regardless of test results. Recruitment occurs in-person, by phone or email, and through online advertisement. A secure online platform is used to facilitate the collation of consent-related materials, digital health records, and responses to self-administered surveys. Participants are followed for up to 18 months, with patient-reported outcomes collected every three months via survey and linked to concurrent digital health data; follow-up includes no in-person involvement. Our planned enrollment is 4,800 participants, including 2,400 SARS-CoV-2 positive and 2,400 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in individuals with and without infection. Patient-reported outcomes include self-reported health function and status, as well as clinical outcomes including health system encounters and new diagnoses.ResultsParticipating sites obtained institutional review board approval. Enrollment and follow-up are ongoing.ConclusionsThis study will characterize medium and long-term sequelae of SARS-CoV-2 infection among a diverse population

Details

Database :
OAIster
Journal :
PloS one; vol 17, iss 3, e0264260; 1932-6203
Notes :
application/pdf, PloS one vol 17, iss 3, e0264260 1932-6203
Publication Type :
Electronic Resource
Accession number :
edsoai.on1344353673
Document Type :
Electronic Resource